Highlights Scandion Oncology A/S

Equities

SCOL

DK0061031895

Market Closed - Nasdaq Stockholm Other stock markets 11:29:31 2024-06-07 am EDT			5-day change	1st Jan Change
0.488 ^SEK	-2.01%		-18.67%	-87.78%

May. 22	Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
May. 22	Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 22	CI
Scandion Confirms Positive Final Phase Ib Data from Pantax Trial with Sco-101	May. 13	CI
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	Mar. 21	CI
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	Mar. 07	CI
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial	Jan. 31	CI
Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101	Jan. 05	CI
Scandion Oncology Announces Presenting Topline Data in the Ongoing Corist Part 3 Study	Dec. 21	CI
Scandion Oncology Completes Pre-Clinical Studies and Identifies Potentially Effective Treatment of Gastric Cancer	Dec. 15	CI
Scandion Oncology Obtains Patent for Combination Cancer Treatment Drug	Nov. 29	MT
Scandion Oncology A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial	Nov. 21	CI
Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data	23-10-15	CI
Scandion Oncology A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Scandion Oncology A/S Announces Data from PANTAX Trial to Be Presented At ESMO Congress 2023	23-08-17	CI
The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion Oncology's Lead Compound SCO-101	23-07-18	CI
Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-26	CI
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22	CI
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Scandion Oncology A/S

Equities

SCOL

DK0061031895

Highlights

Filters